Novavax Reports Its COVID-19 Vaccine is 96% Efficacious, Based on Phase 3 Trial Results

Retrieved on: 2021-03-11 23:56:22

Tags for this article:

Click the tags to see associated articles and topics

Novavax Reports Its COVID-19 Vaccine is 96% Efficacious, Based on Phase 3 Trial Results. View article details on hiswai:

Excerpt

By comparison, Pfizer-BioNTech's vaccine is 95% efficacious against COVID-19 disease, Moderna's is 94%, and Johnson & Johnson's is 66%.

Article found on: time.com